Harmony Biosciences (NASDAQ:HRMY) CFO Sandip Kapadia Sells 20,961 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY opened at $35.91 on Wednesday. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.93. The business has a 50-day simple moving average of $36.92 and a two-hundred day simple moving average of $34.09. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.72 and a current ratio of 3.75. The firm has a market cap of $2.07 billion, a price-to-earnings ratio of 11.29, a price-to-earnings-growth ratio of 0.38 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. The company had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. On average, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HRMY shares. Oppenheimer reissued an “outperform” rating and set a $62.00 price target on shares of Harmony Biosciences in a report on Monday, November 24th. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. UBS Group cut their price target on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a research note on Wednesday, October 15th. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Amundi increased its holdings in Harmony Biosciences by 115.6% in the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after acquiring an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Harmony Biosciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after purchasing an additional 984 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Harmony Biosciences during the 1st quarter valued at $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after buying an additional 33,058 shares in the last quarter. Finally, Voya Investment Management LLC lifted its stake in shares of Harmony Biosciences by 16.8% during the 1st quarter. Voya Investment Management LLC now owns 26,722 shares of the company’s stock valued at $887,000 after buying an additional 3,851 shares in the last quarter. 86.23% of the stock is owned by hedge funds and other institutional investors.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.